(Q36102652)

12 August 2017

1 reference

title

Cancer radioimmunotherapy with alpha-emitting nuclides (English)

1 reference

12 August 2017

4

Alain Faivre-Chauvet

0 references

Stéphane Supiot

2

0 references

Marie Mougin-Degraef

3

object named as

Marie Degraef-Mougin

1 reference

12 August 2017

8

Michel Cherel

1 reference

12 August 2017

Olivier Couturier

1

1 reference

12 August 2017

Thomas Carlier

5

1 reference

12 August 2017

Jean-François Chatal

6

1 reference

12 August 2017

François Davodeau

7

1 reference

12 August 2017

1 May 2005

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

12 August 2017

1 reference

12 August 2017

32

1 reference

12 August 2017

5

1 reference

12 August 2017

601-614

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-005-1803-2

12 August 2017

0 references

cites work

Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-005-1803-2

Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-005-1803-2

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates

21 January 2018

1 reference

12 December 2020

Radioimmunotherapy with alpha-emitting nuclides

1 reference

12 December 2020

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

1 reference

12 December 2020

Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma

1 reference

12 December 2020

Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.

1 reference

12 December 2020

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer

1 reference

12 December 2020

Calculations of cellular microdosimetry parameters for alpha particles and electrons

1 reference

12 December 2020

Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice

1 reference

12 December 2020

Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas

1 reference

12 December 2020

Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy

1 reference

12 December 2020

Comparison of the Radiotoxicity of Two Alpha-Particle-Emitting Immunoconjugates, Terbium-149 and Bismuth-213, Directed against a Tumor-Specific, Exon 9 Deleted (d9) E-Cadherin Adhesion Protein

1 reference

12 December 2020

The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies

1 reference

12 December 2020

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry

1 reference

12 December 2020

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

1 reference

12 December 2020

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

1 reference

12 December 2020

Targeted therapy of cancer with radiolabeled antibodies

1 reference

12 December 2020

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

1 reference

12 December 2020

A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach

1 reference

12 December 2020

Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.

1 reference

12 December 2020

Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial

1 reference

12 December 2020

Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195

1 reference

12 December 2020

Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals

1 reference

12 December 2020

Specific inactivation of sensitized lymphocytes in vitro using antigens labelled with astatine-211

1 reference

12 December 2020

Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study.

1 reference

12 December 2020

Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use

1 reference

12 December 2020

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression

1 reference

12 December 2020

Microdosimetric concepts in radioimmunotherapy.

1 reference

12 December 2020

Heterogeneity of clonogenic cells in acute myeloblastic leukemia

1 reference

12 December 2020

Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).

1 reference

12 December 2020

Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells

1 reference

12 December 2020

Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice

1 reference

12 December 2020

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy

1 reference

12 December 2020

Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate

1 reference

12 December 2020

Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.

1 reference

12 December 2020

1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation

1 reference

12 December 2020

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

1 reference

12 December 2020

Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models

1 reference

12 December 2020

Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis

1 reference

12 December 2020

Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody

1 reference

12 December 2020

In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma

1 reference

12 December 2020

Targeted alpha therapy for cancer

1 reference

12 December 2020

Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi

1 reference

12 December 2020

Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211

1 reference

12 December 2020

Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac

1 reference

12 December 2020

Astatine-211--tellurium radiocolloid cures experimental malignant ascites

1 reference

12 December 2020

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

1 reference

12 December 2020

Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate

1 reference

12 December 2020

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

1 reference

12 December 2020

In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes

1 reference

12 December 2020

Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.

1 reference

12 December 2020

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers

1 reference

12 December 2020

Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49

1 reference

12 December 2020

Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters

1 reference

12 December 2020

Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia

1 reference

12 December 2020

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

12 December 2020

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.

1 reference

12 December 2020

Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides

1 reference

12 December 2020

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia

1 reference

12 December 2020

Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody

1 reference

12 December 2020

Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.

1 reference

12 December 2020

Chimeric and humanized antibodies with specificity for the CD33 antigen

1 reference

12 December 2020

Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy

1 reference

12 December 2020

Increased nuclear damage by high linear energy transfer radioisotopes applicable for radiodirected therapy against radiologic malignancies

1 reference

12 December 2020

The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia

1 reference

12 December 2020

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity

1 reference

12 December 2020

Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia

1 reference

12 December 2020

Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia

1 reference

12 December 2020

Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.

1 reference

12 December 2020

Radioimmunotherapy with alpha-particle-emitting immunoconjugates

1 reference

12 December 2020

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Alpha particle radio-immunotherapy: animal models and clinical prospects

1 reference

12 December 2020

Some microdosmetric data on Astatine-211.

1 reference

12 December 2020

Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells

1 reference

12 December 2020

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

1 reference

12 December 2020

Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149

1 reference

12 December 2020

Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies

1 reference

12 December 2020

Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi

1 reference

12 December 2020

High resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: correlation with histology

1 reference

12 December 2020

Analytic microdosimetry for radioimmunotherapeutic alpha emitters

1 reference

12 December 2020

Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma

1 reference

12 December 2020

Tumor therapy with targeted atomic nanogenerators

1 reference

12 December 2020

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates

1 reference

12 December 2020

Effective alpha-particle-mediated radioimmunotherapy of murine leukemia

1 reference

12 December 2020

Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2

1 reference

12 December 2020

Radiation effects in spheroids of cells exposed to alpha emitters

1 reference

12 December 2020

Improved in vivo stability and tumor targeting of bismuth-labeled antibody

1 reference

12 December 2020

Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin

1 reference

12 December 2020

5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation

1 reference

12 December 2020

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

1 reference

12 December 2020

A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma

1 reference

12 December 2020

Antibody therapy for residual disease in acute myelogenous leukemia

1 reference

12 December 2020

An improved generator for the production of 212Pb and 212Bi from 224Ra

1 reference

12 December 2020

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

1 reference

12 December 2020

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors

1 reference

12 December 2020

Radionuclides for radioimmunotherapy: criteria for selection

1 reference

12 December 2020

Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications

1 reference

12 December 2020

Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction

1 reference

12 December 2020

Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity

1 reference

12 December 2020

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

1 reference

12 December 2020

Comparison of 225actinium chelates: tissue distribution and radiotoxicity

1 reference

12 December 2020

Vascular targeted radioimmunotherapy with 213Bi--an alpha-particle emitter.

1 reference

12 December 2020

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

1 reference

12 December 2020

The development of a [211at]-astatinated endoradiotherapeutic drug: Part I. Localization by α-particle autoradiography in a murine tumor model

1 reference

12 December 2020

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

1 reference

12 December 2020

Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy

1 reference

12 December 2020

Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

1 reference

12 December 2020

In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

1 reference

12 December 2020

Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates

1 reference

12 December 2020

Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system

1 reference

12 December 2020

Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience

1 reference

12 December 2020

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

1 reference

12 December 2020

High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.

1 reference

12 December 2020

Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus.

1 reference

12 December 2020

The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces

1 reference

12 December 2020

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

1 reference

12 December 2020

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

1 reference

12 December 2020

Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy.

1 reference

12 December 2020

A model of cell inactivation by alpha-particle internal emitters

1 reference

12 December 2020

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab

1 reference

12 December 2020

A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy

1 reference

12 December 2020

Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections

1 reference

12 December 2020

Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis

1 reference

12 December 2020

Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody

1 reference

12 December 2020

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

12 December 2020

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

1 reference

12 December 2020

Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer

1 reference

12 December 2020

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

12 December 2020

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S00259-005-1803-2

Identifiers

DOI

1 reference

12 August 2017

1 reference